Posted on 03/15/2020 12:57:15 PM PDT by NCjim
TÜBINGEN, Germany/ Boston March 02, 2020 Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreaks response.
In the discussion, Menichella highlighted the potential of CureVac's mRNA platform for vaccine development based on mRNA technology. "We are very confident that we will be able to develop a potent vaccine candidate within a few months, said CureVac CEO Daniel Menichella. We can rely on the data of a Phase 1 rabies study in which we were able to immunize all participants with a very low dose. On this basis, we are working intensively to achieve a very low dose for the CoV vaccine as well. In addition, CureVac has a GMP-certified production facility which enables us to produce up to ten million vaccine doses in one production run.
CureVac is currently selecting the most suitable vaccine candidates from several constructs based on quality criteria and biological activity. In parallel, the company is coordinating the development of its program with the German Paul Ehrlich Institute (PEI) for accelerated clinical development of these vaccine candidates and is in discussions with other European health authorities. These steps will enable the start of clinical trials in early summer 2020. Two primary study centers have already been identified and are in preparation.
(Excerpt) Read more at curevac.com ...
The democrats will deem it essential to act immediately to ensure that the profit motive is stripped from any entity working on this problem. As a matter of aesthetics, we should not want any vaccine tainted by profit. In fact, we should probably shut down all research not funded by the NIH, which can rush some new grant awards through the system in less than a year. NIH can also ensure that the research funding is precisely allocated to reflect the race and gender distribution of the U.S. population, perhaps with a preference for the Historically Black Colleges and Universities to take on a leadership role. Only in this way can we develop a vaccine that Americans can be proud of.
Too fast for comfort.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.